Canada markets close in 4 hours 27 minutes

Lucid Diagnostics Inc. (LUCD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2350-0.0150 (-1.20%)
As of 10:58AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.2500
Open1.2500
Bid1.2300 x 1300
Ask1.2400 x 1200
Day's Range1.2200 - 1.2500
52 Week Range1.0400 - 1.8500
Volume24,862
Avg. Volume56,804
Market Cap59.279M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that it was notified by the World Trade Center Health Program ("WTCHP") that, due to a clerical error, the EsoGuard® Esophageal DNA test was incorrectly listed as a covered benefit. WTCHP advised Lucid on the further steps required, including engaging directly with its Cl

  • PR Newswire

    Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that its Chairman and Chief Executive Officer, Lishan Aklog, M.D., highlighted Lucid's EsoCheck® Cell Collection Device ("EsoCheck") during testimony before the U.S. House of Representatives' Committee on Small Business. Dr. Aklog was invited by the Congressional committee

  • PR Newswire

    Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that it has contracted with the World Trade Center Health Program ("WTCHP") to provide the EsoGuard® Esophageal DNA test as a covered benefit to the more than 120,000 responders and survivors who participate in the program. The WTCHP provides medical monitoring and treatme